Combined use of topical cyclosporin A and silver sulphadiazine on allografts infected with Pseudomonas in burned rats.
In this study, we investigated the effects of a combination of topical Cyclosporin A (CyA) and silver sulphadiazine on infected and normal skin allografts in burned and unburned rats. Buffalo (Buf) allografts on unburned Lewis (Lew) recipients survived 16.8 +/- 0.9 days after a 10-day course of topical CyA and silver sulphadiazine, as compared to 7.4 +/- 1.1 days for untreated allografts and 18.6 +/- 0.9 days for those receiving CyA only for 10 days. Allografts infected with Pseudomonas aeruginosa and placed on burned recipients survived significantly longer (13.7 +/- 1.1 days) when treated with silver sulphadiazine and topical CyA for 7 days compared to a similar group of animals treated with silver sulphadiazine alone (8.4 +/- 1.0 days). The mortality rate for burned, infected and allografted animals receiving no medication or topical CyA was 50 per cent compared with zero in animals treated with silver sulphadiazine only or combined silver sulphadiazine and topical CyA.
D000287:Administration, Topical; D000818:Animals; D002056:Burns / Q000601:surgery*; D003524:Cyclosporins / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000187:drug effects; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D051381:Rats; D011917:Rats, Inbred Lew; D012837:Silver Sulfadiazine / Q000627:therapeutic use*; D016038:Skin Transplantation; D013411:Sulfadiazine / Q000627:therapeutic use*; D013530:Surgical Wound Infection / Q000188:drug therapy*
D003524:Cyclosporins; D013411:Sulfadiazine; D012837:Silver Sulfadiazine